Clinical Trial

A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring

Study acronym: PANXEON
Recruiting
View on ClinicalTrials.gov →
Summary
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology
Trial Details
NCT Number NCT07700992
Lead Sponsor Università Vita-Salute San Raffaele
Conditions Familial Pancreatic Cancer, Familial Pancreatic Carcinoma, Hereditary Pancreatic Cancer, Hereditary Pancreatitis, Pancreas Cancer, Pancreas Neoplasm, Pancreas Adenocarcinoma, Pancreas Cyst +2 more
Enrollment 600 participants
Start Date 2026-06-03
Primary Completion 2031-12-31 (estimated)
Study Completion 2032-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14